london pharma website re artimist, page-13

Thanks Bluebush - thats cleared up a few of my confusions.

Just following up from your question about open trials - Clydes answer is perfect correct - but in practice many blinded trials end up being virtually open anyway.

This happens because many drugs being tested have side effects that subjects are informed about during recruitment. Subjects know the placebo won’t have side effects. When they experience the side effects (or don’t) they then know whether or not they are receiving the drug. Ive forgotten the statistic but its something like 70% of blinded drug studies are broken by a majority of patients -which then flows on to the clinical staff

The trial design for ArTiMist is interesting (theres a bit of risk there I think) – but positive results should see it becoming a useful complimentary approach next to suppositories which can also be administered in the wild by caregivers before IV treatments can be provided.

Thanks again – Southoz.